Home Podcasts JACC Specialty Journals
JACC Specialty Journals

JACC Specialty Journals

American College of Cardiology 1 957 episodes Nov 3, 2026

In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.

Episodes

Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia
Plasma Proteins Associated with Incident Acute Myocardial Infarction in Asians with Type 2 Diabetes | JACC: Asia Nov 3, 2026 03:59 Commentary by Dr.  Athanasios Sakalidis.
Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia
Real-World Evaluation of a Nationally Mandated Risk Stratification Tool for Destination Therapy LVAD in Japan | JACC: Asia Nov 3, 2026 03:52 Commentary by Dr. Heerajnarain Bulluck.
Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia
Multimodality Imaging-Based Phenotyping and Prognostic Implications of Right Ventricular Involvement in Apical Hypertrophic Cardiomyopathy | JACC: Asia Nov 3, 2026 04:07 Commentary by Dr. Milan Prsa.
Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia
Osteosarcopenia as a Risk Factor for Atrial Fibrillation: A Multi-Cohort Study | JACC: Asia Nov 3, 2026 03:34 Commentary by Dr. Yuhi Fujimoto.
Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia
Epidemiological Analysis and 2040 Projections of Atrial Fibrillation and Flutter in Asia | JACC: Asia Nov 3, 2026 04:24 Commentary by Dr. Yoshihiro Miyamoto.
Advances in a Capsule: October 2026 | JACC: Advances
Advances in a Capsule: October 2026 | JACC: Advances Oct 29, 2026 09:31 Audio Summary of three articles from the October 2026 issue of JACC: Advances.
XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia
XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia Oct 20, 2026 04:35 Commentary by Dr. Yoriyasu Suzuki.
Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia
Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia Oct 20, 2026 04:16 Commentary by Dr. Junjie Yang.
Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia
Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia Oct 20, 2026 03:07 Commentary by Dr. Qinkai Yu.
October 2026 Summary | JACC: CardioOncology
October 2026 Summary | JACC: CardioOncology Oct 20, 2026 01:50 Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and cardiovascular disease. Topics include the mechanisms and clinical implications of
Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology
Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology Oct 20, 2026 02:36 Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of anthracycline cardiotoxicity could lead to therapies that prevent cardiac fibrosis, cardiom
High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology
High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology Oct 20, 2026 05:03 Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He explains what this means for troponin assay selection, baseline testing, and ICI

Recommended